Pretreatment C-reactive protein-to-albumin ratio predicts clinical outcomes in patients with peripheral T-cell lymphoma

[1]  Ying Song,et al.  High C-Reactive Protein to Albumin Ratio Predicts Inferior Clinical Outcomes in Extranodal Natural Killer T-Cell Lymphoma , 2020, Dose-response : a publication of International Hormesis Society.

[2]  Xuelei Ma,et al.  The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma , 2019, Front. Oncol..

[3]  Lixia Zhu,et al.  The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma , 2019, Leukemia & lymphoma.

[4]  A. Salar,et al.  New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO) , 2019, British journal of haematology.

[5]  P. Schuetz,et al.  Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: A prospective study. , 2019, The American journal of medicine.

[6]  R. Advani,et al.  Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial , 2019, The Lancet.

[7]  K. Kihara,et al.  Higher Serum C‐reactive Protein Level Represents the Immunosuppressive Tumor Microenvironment in Patients With Clear Cell Renal Cell Carcinoma , 2018, Clinical genitourinary cancer.

[8]  Ju-Hyun Park,et al.  High level of pre-treatment C-reactive protein to albumin ratio predicts inferior prognosis in diffuse large B-cell lymphoma , 2018, Scientific Reports.

[9]  R. Feng,et al.  Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma , 2018, International Journal of Hematology.

[10]  K. Laribi,et al.  Recent Advances in the Treatment of Peripheral T-Cell Lymphoma. , 2018, The oncologist.

[11]  Yu Hu,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose–response meta-analysis , 2018, Cancer cell international.

[12]  R. Advani,et al.  Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network , 2018, British journal of haematology.

[13]  S. Arques.  Human serum albumin in cardiovascular diseases. , 2018, European journal of internal medicine.

[14]  J. Ashworth,et al.  Role of C-Reactive Protein at Sites of Inflammation and Infection , 2018, Front. Immunol..

[15]  H. Brenner,et al.  Impact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis. , 2018, Cancer treatment reviews.

[16]  J. Joo,et al.  Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma , 2017, Oncotarget.

[17]  Yan Ma,et al.  The prognostic value of C-reactive protein/albumin ratio in human malignancies: an updated meta-analysis , 2017, OncoTargets and therapy.

[18]  N. Schmitz,et al.  How I manage peripheral T‐cell lymphoma, not otherwise specified and angioimmunoblastic T‐cell lymphoma: current practice and a glimpse into the future , 2017, British journal of haematology.

[19]  Wen-Qi Jiang,et al.  Distributed under Creative Commons Cc-by 4.0 the Pretreatment Albumin to Globulin Ratio Predicts Survival in Patients with Natural Killer/t-cell Lymphoma , 2022 .

[20]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Carsten Denkert,et al.  Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.

[22]  B. Nordestgaard,et al.  Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer , 2011, Critical reviews in clinical laboratory sciences.

[23]  B. Nathwani,et al.  Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project , 2022 .

[24]  S. Pileri,et al.  Prognostic Markers in Peripheral T-Cell Lymphoma , 2010, Current hematologic malignancy reports.

[25]  K. Akashi,et al.  Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group , 2010, Bone Marrow Transplantation.

[26]  Stefano A Pileri,et al.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.

[27]  S. Pileri,et al.  Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[29]  L. Staudt,et al.  Gene Expression Profiling of Diffuse Large B-Cell Lymphoma , 2003, Leukemia & lymphoma.

[30]  D. Brenner,et al.  Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. , 1990, The Journal of clinical investigation.